Open Call FETOPEN-01-2016-2017: FET-Open Research and Innovation Actions
The successful exploration of new foundations for radically new future technologies requires supporting a large set of early stage, high risk visionary science and technology projects to investigate new ideas. Here agile, risk-friendly and highly interdisciplinary research approaches are needed with collaborations that are open to all sciences and disciplines and that dissolve the traditional boundaries between them.
Read more ...
Open Call SC1-HCO-17-2017: Support for Large Scale Uptake of Digital Innovation for Active and Healthy Ageing
Several activities on scaling up of digital innovation for active and healthy ageing are currently pursued by the Commission in cooperation with a large number of different stakeholder groups and partner organisations. A coordination and support action is needed to promote the effective uptake and impact of these activities and to leverage additional investments by mobilising other national and regional programmes together with private investments.
Read more ...
Open Call SMEInst-06-2016-2017: Accelerating Market Introduction of ICT Solutions for Health, Well-Being and Ageing Well
The challenge is to help overcome the current gaps in exploitation of promising research results in ICT for Health, Well-being and Ageing well and to stimulate increased availability and market uptake of relevant ICT products and services This concerns both interoperable and secure eHealth solutions for consumers and institutional healthcare delivery building on standards and new ICT solutions and innovation ecosystems for ageing well building on open software platforms, in order to deliver new and more efficient care to European citizens and respond to new market opportunities for SMEs.
Read more ...
Open Call SC1-PM-02-2017: New Concepts in Patient Stratification
Patient stratification aims at grouping patients into disease sub-groups, where the specific pathological processes involved are better defined (clinical/molecular phenotypes). This will lead to the development of targeted therapies, optimizing the intervention to individual patients, thus achieving greater success in treating or curing the patient.
Read more ...
Open Call SC1-PM-16-2017: In-Silico Trials for Developing and Assessing Biomedical Products
Proposals will develop innovative in-silico trials for designing, developing and assessing drugs, radiation and other biomedical and bioactive products. They will build on comprehensive biological and biomedical knowledge management and advanced modelling paradigms in order to be able to simulate the individual human physiology and physiopathology at the
Read more ...
Open Call SC1-PM-17-2017: Personalised Computer Models and in-Silico Systems for Well-being
Proposals should aim at the development of new integrative dynamic computer-models and simulation systems of acceptable validity, with the potential to being reused, build on open service platforms and with application in well-being, health and disease. The projects have to support computer modelling and simulations able to aggregate various information sets
Read more ...
Open Call INNOSUP-02-2016: European SME Innovation Associate - Pilot
This SME-led pilot is an innovation capacity building action to provide at European level a grant to visionary SMEs which have experienced difficulty in recruiting the relevant skills nationally. SMEs are supported to employ a highly-skilled experienced researcher e.g an 'associate' for one year from September 2017.
Read more ...
The successful exploration of new foundations for radically new future technologies requires supporting a large set of early stage, high risk visionary science and technology projects to investigate new ideas. Here agile, risk-friendly and highly interdisciplinary research approaches are needed with collaborations that are open to all sciences and disciplines and that dissolve the traditional boundaries between them. 
Patient stratification aims at grouping patients into disease sub-groups, where the specific pathological processes involved are better defined (clinical/molecular phenotypes). This will lead to the development of targeted therapies, optimizing the intervention to individual patients, thus achieving greater success in treating or curing the patient.